Head and Neck Cancer
November 6
2 min read
On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti–PD-(L)1 antibody.